Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in EGFR-mutated advanced or metastatic non-small cell lung cancer
2010-023869-21Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Progression-free survival. Started Dec 2010; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-023869-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023869-21.